BE902783A - Appareil et procede pour l'administration pulsee d'agents favorisant la croissance. - Google Patents

Appareil et procede pour l'administration pulsee d'agents favorisant la croissance.

Info

Publication number
BE902783A
BE902783A BE0/215282A BE215282A BE902783A BE 902783 A BE902783 A BE 902783A BE 0/215282 A BE0/215282 A BE 0/215282A BE 215282 A BE215282 A BE 215282A BE 902783 A BE902783 A BE 902783A
Authority
BE
Belgium
Prior art keywords
growth promoting
analogues
promoting agents
growth hormone
pulsed delivery
Prior art date
Application number
BE0/215282A
Other languages
English (en)
Original Assignee
Linkie Daniel M
Thorner Michael O
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Linkie Daniel M, Thorner Michael O filed Critical Linkie Daniel M
Publication of BE902783A publication Critical patent/BE902783A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/168Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
    • A61M5/172Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
    • A61M5/1723Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/25Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/27Growth hormone [GH], i.e. somatotropin
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00Peptide or protein sequence
    • Y10S930/01Peptide or protein sequence
    • Y10S930/12Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Fodder In General (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Procédé et appareil à programme (18, 21, 23) pour le traitement efficace d'un animal vivant, suivant lequel on administre une dose dynamique de facteur de dégagement de l'hormone de croissance ou de ses analogues ou on administre à titre chronique l'hormone de croissance ou ses analogues en régime subdésensibilisant. Procédé de diagnostic chez l'animal vivant atteint d'une insenibilité de l'hypophyse antérieure à l'égard du facteur de dégagement de l'hormone de croissance ou de ses analogues.
BE0/215282A 1984-06-29 1985-06-28 Appareil et procede pour l'administration pulsee d'agents favorisant la croissance. BE902783A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/626,400 US4747825A (en) 1984-06-29 1984-06-29 Apparatus and methodology for pulsed administration of growth promoting agents

Publications (1)

Publication Number Publication Date
BE902783A true BE902783A (fr) 1985-10-16

Family

ID=24510242

Family Applications (1)

Application Number Title Priority Date Filing Date
BE0/215282A BE902783A (fr) 1984-06-29 1985-06-28 Appareil et procede pour l'administration pulsee d'agents favorisant la croissance.

Country Status (16)

Country Link
US (1) US4747825A (fr)
EP (1) EP0190199A4 (fr)
JP (1) JPS61502519A (fr)
AU (1) AU4605385A (fr)
BE (1) BE902783A (fr)
BR (1) BR8506785A (fr)
DK (1) DK294685A (fr)
FI (1) FI852516L (fr)
IL (1) IL75671A0 (fr)
MW (1) MW686A1 (fr)
NO (1) NO852603L (fr)
OA (1) OA08214A (fr)
PT (1) PT80738B (fr)
RO (1) RO95012A (fr)
WO (1) WO1986000233A1 (fr)
ZA (1) ZA854916B (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089472A (en) * 1988-01-26 1992-02-18 Laboratorios Serono S.A. Use of growth hormone releasing factor for improving mental function
US5065748A (en) * 1989-11-14 1991-11-19 University Of South Florida Method of diagnosing growth hormone disorders employing somatostatin and growth hormone releasing hormone
US5065747A (en) * 1989-11-21 1991-11-19 University Of South Florida Method for improving the accuracy of diagnosis of growth hormone deficiency
US5428013A (en) * 1991-01-04 1995-06-27 Mugica; Jesus D. Differential diagnosis and treatment of the states of growth hormone insufficiency (or deficiency) with an alpha-2-adrenergic agonist and a growth hormone releasing peptide
US7910624B1 (en) 1995-03-03 2011-03-22 The Trustees Of Boston University Compositions for the treatment of blood disorders
EP0731712A4 (fr) * 1993-10-29 2005-11-09 Univ Boston Compositions physiologiquement stables d'acide butyrique, de sels et de derives d'acide butyrique, utilisees comme agents antineoplasiques
JPH10511095A (ja) * 1994-12-19 1998-10-27 ベス イスラエル ディーコネス メディカル センター インコーポレイテッド 副甲状腺ホルモン又はその作動薬の低用量継続投与
US6403647B1 (en) 1996-07-26 2002-06-11 Susan P. Perrine Pulsed administration of compositions for the treatment of blood disorders
US5939456A (en) * 1996-07-26 1999-08-17 Perrine; Susan P. Pulsed administration of compositions for the treatment of blood disorders
EP1886677A1 (fr) 1996-07-26 2008-02-13 Susan P. Perrine Composition comprenant un agent d'induction et agent antiviral pour le traitement de maladies sanguines, virales et cellulaires
ES2146530B1 (es) * 1997-12-26 2001-04-16 Consejo Superior Investigacion Utilizacion del factor de crecimiento igf-i en la fabricacion de composiciones utiles en el tratamiento de la ataxia cerebelar.
CA2324426A1 (fr) * 1998-02-11 1999-08-19 Douglas V. Faller Compositions et techniques de traitement de la mucoviscidose
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
WO2010105112A1 (fr) * 2009-03-11 2010-09-16 Hemaquest Pharmaceuticals, Inc. Détection d'acides gras à chaîne courte dans des échantillons biologiques
WO2011014775A1 (fr) 2009-07-31 2011-02-03 The Brigham And Women's Hospital, Inc. Modulation de l’expression de sgk1 dans les cellules th17 pour moduler les réponses immunitaires médiées par th17
WO2011038224A1 (fr) 2009-09-24 2011-03-31 Trustees Of Boston University Procédés pour le traitement de troubles viraux
WO2011072086A1 (fr) 2009-12-08 2011-06-16 Hemaquest Pharmaceuticals, Inc. Procédés et régimes à faible dose pour traiter des troubles des globules rouges
US20110245154A1 (en) 2010-03-11 2011-10-06 Hemaquest Pharmaceuticals, Inc. Methods and Compositions for Treating Viral or Virally-Induced Conditions
WO2012106281A2 (fr) 2011-01-31 2012-08-09 The General Hospital Corporation Molécules trail multimodales et leurs utilisations en thérapies cellulaires
US9585930B2 (en) 2011-03-20 2017-03-07 Trustees Of Boston University Therapeutic agent for emphysema and COPD
US9480696B2 (en) 2011-05-04 2016-11-01 Trustees Of Boston University Proton-motive force stimulation to potentiate aminoglycoside antibiotics against persistent bacteria
US20140227293A1 (en) 2011-06-30 2014-08-14 Trustees Of Boston University Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
EP2766041B1 (fr) 2011-10-12 2018-12-05 Children's Medical Center Corporation Compositions combinatoires et méthodes de traitement d'hémoglobinopathies
US9243037B2 (en) 2011-11-10 2016-01-26 Trustees Of Boston College Gramicidin a mutants that function as antibiotics with improved solubility and reduced toxicity
US9173884B2 (en) 2011-11-30 2015-11-03 Trustees Of Boston College Inhibitors of phosphodiesterase 11 (PDE11)
US10513540B2 (en) 2012-07-31 2019-12-24 The Brigham And Women's Hospital, Inc. Modulation of the immune response
WO2014035474A1 (fr) 2012-08-30 2014-03-06 The General Hospital Corporation Compositions et méthodes de traitement du cancer
BR112015008118A2 (pt) 2012-10-12 2017-12-05 Brigham & Womens Hospital Inc reforço da resposta imune
US20150366890A1 (en) 2013-02-25 2015-12-24 Trustees Of Boston University Compositions and methods for treating fungal infections
EP3036226B1 (fr) 2013-08-22 2020-01-08 The General Hospital Corporation Inhibiteurs de la 12/15-lipoxygénase- humaine
EP3038625A4 (fr) 2013-08-29 2017-08-23 Trustees of Boston University Produits métaboliques intermédiaires pour potentialiser des antibiotiques aminoglycosides dans des infections bactériennes
ES2909014T3 (es) 2013-11-26 2022-05-04 Brigham & Womens Hospital Inc Composiciones y métodos para modular una respuesta inmunitaria
WO2015089321A2 (fr) 2013-12-11 2015-06-18 The General Hospital Corporation Utilisation de protéines d'hormone anti-mullerienne (amh) pour la contraception et la préservation de la réserve ovarienne
US20170107300A1 (en) 2014-03-21 2017-04-20 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
WO2015164364A2 (fr) 2014-04-25 2015-10-29 The Brigham And Women's Hospital, Inc. Procédés de manipulation de l'alpha-fœtoprotéine (afp)
EP3134733B1 (fr) 2014-04-25 2020-10-14 The Brigham and Women's Hospital, Inc. Test et procédé pour traiter des patients ayant des maladies à médiation immunitaire
WO2016044707A1 (fr) 2014-09-18 2016-03-24 Cedars-Sinai Medical Center Compositions et procédés de traitement de la fibrose
AU2016206682B2 (en) 2015-01-14 2021-11-11 The Brigham And Women's Hospital, Inc. Treatment of cancer with anti-LAP monoclonal antibodies
WO2016172479A1 (fr) 2015-04-22 2016-10-27 Cedars-Sinai Medical Center Oligopeptides amers administrés par voie entérique pour le traitement du diabète de type 2
WO2016196664A1 (fr) 2015-06-01 2016-12-08 Cedars-Sinai Medical Center Procédés et utilisation de composés qui se lient à rela de nf-kb
CN116712552A (zh) 2015-06-19 2023-09-08 波士顿大学托管委员会 用于治疗疱疹病毒诱导的病况的方法和组合物
MX2018001075A (es) 2015-07-28 2019-04-15 Vyome Therapeutics Ltd Agentes terapeuticos y profilacticos antibacterianos.
WO2017058828A1 (fr) 2015-09-28 2017-04-06 Children's Hospital Los Angeles Méthodes de traitement de maladies à médiation par les macrophages pro-inflammatoires positifs à l'erbb4
US20190255107A1 (en) 2015-10-09 2019-08-22 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
US20200016202A1 (en) 2016-10-07 2020-01-16 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
EP3752532A1 (fr) 2018-02-12 2020-12-23 Diabetes-Free, Inc. Anticorps monoclonaux anti-cd40 humain antagonistes améliorés
WO2020102454A1 (fr) 2018-11-13 2020-05-22 Regents Of The University Of Minnesota Peptides ciblant le cd40 et leurs utilisations
SG11202113215UA (en) 2019-05-31 2021-12-30 Viracta Subsidiary Inc Methods of treating virally associated cancers with histone deacetylase inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3498228A (en) * 1967-05-01 1970-03-03 Charles A Blumle Portable infusion pump
US3559644A (en) * 1967-12-14 1971-02-02 Robert F Shaw Liquid infusion apparatus
US3809871A (en) * 1972-12-01 1974-05-07 Nasa Programmable physiological infusion
US4273122A (en) * 1976-11-12 1981-06-16 Whitney Douglass G Self contained powered injection system
US4313439A (en) * 1980-03-24 1982-02-02 Biotek, Inc. Automated, spring-powered medicament infusion system
DE3015777A1 (de) * 1980-04-24 1981-10-29 Ferring Arzneimittel Gmbh, 2300 Kiel Vorrichtung zur intermittierenden pulsatorischen applikation von fluessigen arzneimitteln
US4306553A (en) * 1980-07-22 1981-12-22 The Regents Of The University Of Minnesota Method of maintaining the fluidity of hormone solutions for parenteral administration
US4517181A (en) * 1982-09-15 1985-05-14 The Salk Institute For Biological Studies Mammalian PGRF
US4529595A (en) * 1983-01-13 1985-07-16 The Salk Institute For Biological Studies GRF Analogs

Also Published As

Publication number Publication date
WO1986000233A1 (fr) 1986-01-16
PT80738B (en) 1986-12-11
EP0190199A1 (fr) 1986-08-13
BR8506785A (pt) 1986-11-25
MW686A1 (en) 1987-03-11
FI852516A0 (fi) 1985-06-26
AU4605385A (en) 1986-01-24
ZA854916B (en) 1986-02-26
FI852516L (fi) 1985-12-30
EP0190199A4 (fr) 1987-12-01
OA08214A (en) 1987-10-30
IL75671A0 (en) 1985-10-31
US4747825A (en) 1988-05-31
JPS61502519A (ja) 1986-11-06
DK294685A (da) 1985-12-30
PT80738A (en) 1985-07-01
DK294685D0 (da) 1985-06-28
RO95012A (fr) 1988-09-15
NO852603L (no) 1985-12-30

Similar Documents

Publication Publication Date Title
BE902783A (fr) Appareil et procede pour l'administration pulsee d'agents favorisant la croissance.
Stern et al. Pituitary-adrenal responsiveness during lactation in rats
Edmonds et al. Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine
Rosenberg et al. Prophylaxis of postoperative leg vine thrombosis by low dose subcutaneous heparin or peroperative calf muscle stimulation: a controlled clinical trial.
Burke The triiodothyronine suppression test
Smith et al. Increasing the effectiveness of gold therapy in rheumatoid arthritis
NO933044D0 (no) Fremgangsmaate for behandling av osteoporose
Constas The effects of adrenaline, noradrenaline, and isoprenaline on parkinsonian tremor
DE3880587D1 (de) Verwendung von bestimmten calcium-citrate-malaten zur herstellung einer pharmazeutischen zubereitung fuer die behandlung von osteoporose.
NZ209743A (en) Use of growth hormone to enhance ruminant mammary development
Mazer et al. Evaluation of the constitutional effects of large doses of estrogenic principle
Grund et al. Hyperthyroxinemia in patients receiving thyroid replacement therapy
JACOBS Observations of neuropathic (Charcot) joints occurring in diabetes mellitus
Innerfield et al. Bradykinin antagonism following oral protease therapy
Singer Latency of pancreatic fluid secretory response to intestinal stimulants in the dog.
Burhol et al. Single subcutaneous doses of histamine and pentagastrin in gastric fistula chickens
Lincoln Physiological mechanisms governing the transfer of milk from mother to young
KRUGMAN et al. TRH test as an index of suppression compared with the thyroid radioiodine uptake in euthyroid goitrous patients treated with thyroxine
Griswold et al. Lymphocyte responses to phytohemagglutinin in rheumatoid arthritis and glomerulonephritis and the effects of immunosuppression
Fleischer Effect of oxytetracycline and chloramphenicol on the exocrine pancreatic function in the rat
SUTRO et al. Basis and treatment of calcification of tendinocapsular tissues, especially the supraspinatus tendon
Haggendal et al. The effect of triiodothyronine treatment on the catecholamine content of the blood during infusion of adrenaline in man
SU787995A1 (ru) Способ дифференцировани т и в лимфоцитов человека
Sholz Utilization of the reticular groove contraction in adult cattle: A therapeutical alternative for the practitioner?
Riggs et al. Effect of calcium infusion on serum calcium levels in hypothyroidism

Legal Events

Date Code Title Description
RE Patent lapsed

Owner name: THORNER MICHAEL O.

Effective date: 19880630

Owner name: LINKIE DANIEL M

Effective date: 19880630